TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37480410

Group type: EXPERIMENTAL
Intervention: Aspergillus-positive patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: Aspergillus-negative patients
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Aspergillus presence
Number of subjects: 382
Study: 37480432

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant low-potency topical corticosteroids (TCS) every 4 weeks for 16 weeks
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant low-potency topical corticosteroids (TCS)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo with concomitant low-potency topical corticosteroids (TCS)
Number of subjects: 162
Study: 37480520

Group type: EXPERIMENTAL
Intervention: LL-37 cream applied twice a week for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream applied twice a week for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LL-37 cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 37480797

Group type: EXPERIMENTAL
Intervention: smART+ -guided nutrition
Number of subjects: 98

Group type: COMPARATOR
Intervention: ESPEN-guideline-based nutrition (Control)
Number of subjects: 98
Study: 37480800

Group type: EXPERIMENTAL
Intervention: Pre-cardioversion mean AFR of patients relapsed to AF (332 ± 64 fpm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pre-cardioversion mean AFR of patients maintaining sinus rhythm (378 ± 59 fpm)
Number of subjects: 32
Study: 37480840

Group type: EXPERIMENTAL
Intervention: Online sleep diary system (SHUTi intervention)
Number of subjects: 45598
Study: 37480908

Group type: EXPERIMENTAL
Intervention: Focal CAD
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Diffuse CAD
Number of subjects: 117
Study: 37480994

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy plus chemotherapy (HFRT), 60 Gy over 25 fractions, administered five times each week.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy plus chemotherapy (CFRT), 69.96 Gy over 33 fractions, administered five times each week.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups experienced acute grade 1 or 2 toxicities including skin toxicity, oral mucositis, difficulty swallowing, xerostomia; no acute grade 3 or 4 toxicities reported.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy plus chemotherapy (HFRT).
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy plus chemotherapy (CFRT).
Number of subjects: 28
Study: 37481003

Group type: EXPERIMENTAL
Intervention: Dual-action tissue (DAT) clip
Number of subjects: 107
Study: 37481065

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging-Guided Transrectal Prostate Laser Ablation
Number of subjects: 0
Study: 37481150

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (AA)
Number of subjects: 22
Study: 37481477

Group type: EXPERIMENTAL
Intervention: Germline whole genome sequencing (WGS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Multigene panel testing
Number of subjects: 9
Study: 37481493

Group type: EXPERIMENTAL
Intervention: Navigation-assisted surgery
Number of subjects: 17
Study: 37481515

Group type: EXPERIMENTAL
Intervention: HAI oxaliplatin in combination with modified systemic FOLFIRI plus targeted therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic FOLFIRI plus targeted therapy
Number of subjects: 0
Study: 37481608

Group type: EXPERIMENTAL
Intervention: Third-generation CD19-directed CAR T cells (CARTs)
Number of subjects: 13
Study: 37481707

Group type: EXPERIMENTAL
Intervention: Variable flow CPAP device
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ventilator CPAP
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bubble CPAP
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CPAP (general)
Number of subjects: 138
Study: 37481756

Group type: EXPERIMENTAL
Intervention: Vibration group (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 24
Study: 37481816

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) - defined as a combination of a minimum of 3 medications in 4 drug classes (antiplatelet drugs, statins, β blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).
Number of subjects: 8311

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 8311

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) in PCI group
Number of subjects: 8311

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) in CABG group
Number of subjects: 8311
Study: 37482128

Group type: EXPERIMENTAL
Intervention: Hair samples from premature neonates
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prolonged NICU exposure to non-invasive respiratory support devices and gastric tubes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control neonates
Number of subjects: 45
Study: 37482172

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 20 mg/kg/d, twice daily for 4 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 37482217

Group type: EXPERIMENTAL
Intervention: Diet similar to the DASH diet (25% total fat: 6% SFA)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Average American diet (AAD) (37% total fat: 16% SFA)
Number of subjects: 166
Study: 37482499

Group type: EXPERIMENTAL
Intervention: Adaptive 8-week weight loss program including evidence-based lifestyle recommendations for diet, physical activity, and self-weighing; support through text messages, emails, and video-based problem-solving sessions.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Adaptive 8-week weight loss program
Number of subjects: 28
Study: 37482512

Group type: EXPERIMENTAL
Intervention: Presurgical PSMA-PET
Number of subjects: 277

Group type: COMPARATOR
Intervention: Presurgical CAPRA score alone
Number of subjects: 277
Study: 37482564

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0
Study: 37482646

Group type: EXPERIMENTAL
Intervention: Nasal microbiota of ALS patients
Number of subjects: 66
Study: 37482821

Group type: EXPERIMENTAL
Intervention: Whole-body vibration in addition to diet instructions, pelvic floor exercises, and static abdominal exercises for six weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pelvic floor exercises, static abdominal exercises, and diet instructions
Number of subjects: 40
Study: 37482878

Group type: EXPERIMENTAL
Intervention: Autogenous dentin nanoparticles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Allograft bone grafts
Number of subjects: 20
Study: 37482926

Group type: EXPERIMENTAL
Intervention: Single FMT treatment
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Repeated FMT treatments
Number of subjects: 183
Study: 37482940

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 396
Study: 37482992

Group type: EXPERIMENTAL
Intervention: Kundalini yoga (KY) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Memory enhancement training (MET)
Number of subjects: 22
Study: 37483071

Group type: EXPERIMENTAL
Intervention: BFI-751
Number of subjects: 0

Group type: COMPARATOR
Intervention: EU ustekinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: US ustekinumab
Number of subjects: 0
Study: 37483161

Group type: EXPERIMENTAL
Intervention: Complement activation within the first weeks after allo-HSCT
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Complement activation
Number of subjects: 85
Study: 37483544

Group type: EXPERIMENTAL
Intervention: CM310 (300 mg) every 2 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 37483552

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37483617

Group type: EXPERIMENTAL
Intervention: Inter-alpha-trypsin inhibitor heavy chain 4
Number of subjects: 0
Study: 37483623

Group type: EXPERIMENTAL
Intervention: Modified immune cell (MIC) infusions
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (control)
Number of subjects: 25
Study: 37484009

Group type: EXPERIMENTAL
Intervention: Oil palm phenolic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37484196

Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 64

Group type: COMPARATOR
Intervention: Water cues
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol Taste Test (ATT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TNF-α release in the alcohol cue condition
Number of subjects: 64
Study: 37484210

Group type: EXPERIMENTAL
Intervention: Serum total cortisol (t-Cort) levels in stable outpatients with ACLD
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Clinical stages of ACLD (S0 to S5)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Serum total cortisol (t-Cort) levels
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Increased levels of bile acids and systemic inflammation (interleukin-6 levels)
Number of subjects: 137
Study: 37484496

Group type: EXPERIMENTAL
Intervention: 750 mg SIM0417 plus 100 mg ritonavir
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 300 mg SIM0417 plus 100 mg ritonavir
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 37484539

Group type: EXPERIMENTAL
Intervention: Nutri-Score V.2.0 (graphically modified version with a black 'ultraprocessed' banner)
Number of subjects: 21159

Group type: COMPARATOR
Intervention: No front-of-pack label (control)
Number of subjects: 21159
Study: 37484855

Group type: EXPERIMENTAL
Intervention: Productive art-based activities (2 hours per week for 12 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no productive art-based activity)
Number of subjects: 73
Study: 37484872

Group type: EXPERIMENTAL
Intervention: PrEP integrated into maternal and child health (MCH) clinics
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PrEP training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Auditory and visual privacy in PrEP and HIV testing service delivery spaces
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Supervision visits
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Availability of PrEP in MCH
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Risk assessment screening tool (RAST) availability
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PrEP cards availability
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Number of service and commodity gaps per facility
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Most frequent gaps
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mean number of gaps by facility level
Number of subjects: 55
Study: 37484961

Group type: EXPERIMENTAL
Intervention: Standard program (3 sessions/week for 12 weeks)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Alternative program (1 session/week for the first four weeks, then 2 sessions/week for the next 16 weeks)
Number of subjects: 185
Study: 37485329

Group type: EXPERIMENTAL
Intervention: Personalized digital therapeutic group
Number of subjects: 324

Group type: COMPARATOR
Intervention: Conventional education-based rehabilitation group
Number of subjects: 324
Study: 37485383

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (16g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pea sprouts (placebo)
Number of subjects: 12
Study: 37485388

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37485397

Group type: EXPERIMENTAL
Intervention: Multiple drugs given per routine care
Number of subjects: 0
Study: 37485436

Group type: EXPERIMENTAL
Intervention: Postpartum web- and phone-based lifestyle program
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tailored lifestyle counseling by a registered dietitian
Number of subjects: 44
Study: 37485564

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day on days 1-14 of every 21-day cycle in combination with R-ESHAP at standard doses
Number of subjects: 46
Study: 37485589

Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin 240 IU (400 μg) IH
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU (17 μg) IM
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous oxytocin 5 IU (8.5 μg) IV
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin (Group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular oxytocin (Group 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhaled oxytocin (Group 2)
Number of subjects: 31
Study: 37485887

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.8 ± 0.1 mmoL/L [49.9 ± 2.3 mg/dL])
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy controls (matched)
Number of subjects: 63
Study: 37486024

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 20
Study: 37486082

Group type: EXPERIMENTAL
Intervention: V122I carriers with ATTR-CM
Number of subjects: 278

Group type: COMPARATOR
Intervention: V122I carriers without ATTR-CM
Number of subjects: 278

Group type: COMPARATOR
Intervention: HF controls
Number of subjects: 278
Study: 37486184

Group type: EXPERIMENTAL
Intervention: Two-minute step test (2MST)
Number of subjects: 51
Study: 37486343

Group type: EXPERIMENTAL
Intervention: Rucaparib (PARP inhibitor)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy after PARPi progression
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy after progression on PARPi
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 42
Study: 37486363

Group type: EXPERIMENTAL
Intervention: Elevated responsivity of brain regions implicated in reward valuation to thin models
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Elevated responsivity of brain regions implicated in reward valuation to high-calorie binge foods
Number of subjects: 146
Study: 37486372

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy combined with partial splenic embolization (EP group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Endoscopic therapy alone (E group)
Number of subjects: 110
Study: 37486616

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy targeting CD19 and/or CD22
Number of subjects: 134
Study: 37486633

Group type: EXPERIMENTAL
Intervention: Mailed nicotine patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37486650

Group type: EXPERIMENTAL
Intervention: Intravenous Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Iron supplementation
Number of subjects: 0
Study: 37486652

Group type: EXPERIMENTAL
Intervention: Cabergoline 1 mg once
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 37486732

Group type: EXPERIMENTAL
Intervention: PC4L system (intervention group)
Number of subjects: 558

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 558
Study: 37486738

Group type: EXPERIMENTAL
Intervention: Wearable biosensor (Wrist Angel) monitoring physiological signals (pulse, electrodermal activity, skin temperature, acceleration) for 8 weeks.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clinical interviews and questionnaires at baseline, weeks 4, 7, and 8.
Number of subjects: 18
Study: 37486755

Group type: EXPERIMENTAL
Intervention: Digital live seminar (2.5-hour midwife-assisted, included exercises on empathy and clear communication)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Web-based application (fully automated, 9 consecutive training lessons with same content as live seminar)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 657
Study: 37486759

Group type: EXPERIMENTAL
Intervention: Senior Companion Program Plus (SCP Plus)
Number of subjects: 114
Study: 37486770

Group type: EXPERIMENTAL
Intervention: Predictive model for injury risk
Number of subjects: 450

Group type: COMPARATOR
Intervention: Not using a prediction model
Number of subjects: 450
Study: 37486775

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 4 mg daily
Number of subjects: 7769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7769
Study: 37486952

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy-protein (BEP) supplementation and iron-folic acid (IFA) tablets
Number of subjects: 1897

Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) alone
Number of subjects: 1897
Study: 37487056

Group type: EXPERIMENTAL
Intervention: Palbociclib + AI
Number of subjects: 270

Group type: COMPARATOR
Intervention: AI alone
Number of subjects: 270
Study: 37487144

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) in PORTEC-1 trial
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT) in PORTEC-2 trial
Number of subjects: 880

Group type: COMPARATOR
Intervention: No adjuvant therapy in PORTEC-1 trial
Number of subjects: 880

Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) in PORTEC-2 trial
Number of subjects: 880
Study: 37487169

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) once every 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg) once every 3 weeks + Radiotherapy (RT)
Number of subjects: 32
Study: 37487433

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced PCD-CT scans measuring CT-values of the blood pool on 70 keV VMI series.
Number of subjects: 329
Study: 37487656

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion imaging with positron emission tomography (PET) using tracers
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Coronary CT angiography (CTA)
Number of subjects: 1000
Study: 37487677

Group type: EXPERIMENTAL
Intervention: Delphi survey criteria for IMCU admission
Number of subjects: 81

Group type: COMPARATOR
Intervention: Delphi survey round 1
Number of subjects: 81

Group type: COMPARATOR
Intervention: Delphi survey round 2
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Criteria classification
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Influence of specialty and institution type
Number of subjects: 81
Study: 37487682

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of venous congestion (IVC, HV, PV, IRV)
Number of subjects: 350
Study: 37487764

Group type: EXPERIMENTAL
Intervention: Parent BMI
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Parent income
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Parent education
Number of subjects: 95
Study: 37487804

Group type: EXPERIMENTAL
Intervention: Circulating microRNA 10a
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Circulating microRNA 92a
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Circulating microRNA 155
Number of subjects: 461
Study: 37488191

Group type: EXPERIMENTAL
Intervention: Samuraciclib (360 mg once daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Samuraciclib monotherapy in TNBC
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Samuraciclib in combination with fulvestrant
Number of subjects: 81
Study: 37488286

Group type: EXPERIMENTAL
Intervention: pyrotinib (CF cohort, n=28)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: pyrotinib (CU cohort, n=12)
Number of subjects: 48

Group type: COMPARATOR
Intervention: physician's therapy of choice (RWS cohort, n=8)
Number of subjects: 48
Study: 37488287

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade with adebrelimab (two doses before surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade with adebrelimab
Number of subjects: 30
Study: 37488289

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2-overexpressing metastatic breast cancer (n=72)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (n=74)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer (n=40)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer with ERBB2 expression below the median (n=14)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in HER2 non-expressing metastatic breast cancer with ERBB2 expression above the median (n=10)
Number of subjects: 177
Study: 37488291

Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Number of subjects: 10
Study: 37488349

Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae Plane Block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 80
Study: 37488368

Group type: EXPERIMENTAL
Intervention: Intervention to improve Advance Care Planning (ACP) during the COVID pandemic
Number of subjects: 20
Study: 37488446

Group type: EXPERIMENTAL
Intervention: 2-OHOA (sodium 2-hydroxyoleate) at a maximum tolerated dose (MTD) of 12,000 mg/daily
Number of subjects: 54
Study: 37488448

Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 108
Study: 37488472

Group type: EXPERIMENTAL
Intervention: Former preterm-born adolescents
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Term-born adolescents
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Both groups (term and preterm)
Number of subjects: 1491
Study: 37488580

Group type: EXPERIMENTAL
Intervention: Agalsidase beta infusions <90 min
Number of subjects: 2678

Group type: COMPARATOR
Intervention: Agalsidase beta infusions ≥90 min
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: Infusion rates
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: Patients <30 kg
Number of subjects: 2678

Group type: COMPARATOR
Intervention: Patients ≥30 kg
Number of subjects: 2678

Group type: EXPERIMENTAL
Intervention: Anti-agalsidase beta antibody-positive patients
Number of subjects: 2678
Study: 37488588

Group type: EXPERIMENTAL
Intervention: MT-assisted ambulation up to three times daily, guided by the Johns Hopkins Mobility Goal Calculator, until hospital discharge or after 10 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MT-assisted ambulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0